Our Recommendations
New Publications
- Tackling antimalarial drug resistance (2020)
- Regional stakeholder meeting on the response to antimalarial drug resistance in Africa (2024)
- Extending the WHO scheme for external quality assessment of nucleic acid amplification testing for monitoring antimalarial drug resistance: meeting report, 14 July 2023 (2025)
- Antimalarial Drug Resistance and Novel Targets for Antimalarial Drug Discovery (2020)
- Drug Resistant Malaria. Current Status (2024)
Filter
13
Featured
Language
Document type
Studies & Reports
6
Resource Platforms
3
Guidelines
2
Training Material
1
Strategic & Response Plan
1
Countries / Regions
Africa
1
Authors & Publishers
Publication Years
Category
Clinical Guidelines
1
Efficacious antimalarial medicines are critical to malaria control and elimination. Continuous monitoring of their efficacy is needed to inform treatment policies in malaria-endemic countries, and to ensure early detection of, and response to, drug resistance.
Pour combattre et éliminer le paludisme, il est essentiel de disposer de médicaments antipaludiques efficaces. Un suivi régulier de l’efficacité des médicaments s’impose pour orienter les politiques de traitement dans les pays d’endémie palustre et assurer la détection précoce de la ph...
Para controlar y eliminar el paludismo (o malaria) es fundamental contar con fármacos antipalúdicos eficaces. Para fundamentar las políticas de tratamiento en los países donde esta enfermedad es endémica, y para garantizar la pronta detección de toda farmacorresistencia y una adecuada respuest...
WHO recommends artemisinin-based combination therapies for treating uncomplicated malaria, alongside studies to monitor treatment effectiveness. Given the threat of antimalarial resistance, including partial resistance in several African countries, molecular tools are vital for tracking resistance. ...
Effective malaria case management requires quick access to diagnostics and antimalarial treatments to reduce illness and death. Artemisinin-based combination therapy (ACT) has been essential to malaria treatment since 2001, as it combines artemisinin for rapid parasite reduction with a partner drug ...
Meeting report, Kampala, Uganda,
7–8 November 2023
The Strategy to respond to antimalarial drug resistance in Africa is a technical and advocacy document, grounded in the best available evidence to date and aimed at minimizing the threat and impact of antimalarial drug resistance of Plasmodium falciparum parasites in Africa. Its objectives are to: i...
La Stratégie de riposte face à la résistance aux antipaludiques en Afrique est un document technique de sensibilisation qui se fonde sur les bases factuelles les plus solides dont on dispose et vise à réduire au maximum la menace et l’impact de la résistance aux antipaludiques de Plasmodium ...
Antimalarial drug resistance has emerged as a threat to global malaria control efforts, particularly in the Greater Mekong subregion. Drawing on data collected through more than 1000 therapeutic efficacy studies as well as molecular marker studies of Plasmodium falciparum drug resistance, the Report...
Infection and Drug Resistance 2020:13 4047–4060
Launch of the WHO Report on antimalarial drug efficacy, resistance and response: 10 years of surveillance (2010–2019). Key findings
The reports bring together the latest findings and conclusions about the state of resistance to artemisinins and artemisinin-based combination therapy (ACT), summarize WHO’s current policy and treatment recommendations, and highlight areas of concern.
